James Birchenough's questions to SNSS leadership • Q4 2016
Question
James Birchenough of Wells Fargo Securities, LLC asked for specifics on the SNS-062 binding site and its competitive differentiation, and whether the initial trial patients would be ibrutinib failures with the C481S mutation.
Answer
President and CEO Daniel Swisher explained that SNS-062 binds away from the C481S mutation site, preserving its efficacy, and noted their lead position among non-covalent inhibitors. VP of Clinical Development Linda Neuman confirmed the trial will enroll patients who have failed a prior BTK inhibitor, anticipating most will have the C481S mutation.